Press "Enter" to skip to content

England’s NICE rebuffs Pfizer and Astellas’ Xtandi in nonmetastatic prostate cancer – FiercePharma

admin 0

England’s NICE rebuffs Pfizer and Astellas’ Xtandi in nonmetastatic prostate cancer  FiercePharma

Pfizer and Astellas’ Xtandi lost its bid to expand to the U.K. market after an English watchdog said the prostate cancer drug proved ineffective in extending …

“prostate cancer” – Google News

(Visited 3 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *